Literature DB >> 9779659

Long-term follow-up of levodopa responsiveness in generalized dystonia.

R B Dewey1, M D Muenter, A Kishore, B J Snow.   

Abstract

OBJECTIVES: To assign an accurate diagnosis to patients with dystonia based on the presence of sustained levodopa responsiveness and to determine whether motor fluctuations occur in patients with dystonia who are withheld from levodopa. PATIENTS AND METHODS: Patients with generalized dystonia who responded to treatment in the 1970s with levodopa/carbidopa were surveyed by phone and then examined during a 3-day levodopa holiday. Functional imaging with fluorodopa positron emission tomography was performed on a subset of patients.
RESULTS: In the phone interview, 4 of 7 patients with a diagnosis of dopa-responsive dystonia reported the wearing-off effect a short while (within 4-8 hours) after missing a dose of levodopa. Five patients with dopa-responsive dystonia were examined repetitively during levodopa withdrawal, and 3 developed recurrent symptoms of dystonia as the drug was withheld. In each case, worsening of dystonia did not occur until 29 hours or more after levodopa withdrawal, providing evidence for a response profile similar to the long duration response described in Parkinson disease. No significant changes were seen in the dystonia scores of the 3 patients with idiopathic torsion dystonia who were withheld from levodopa.
CONCLUSIONS: We suggest that the subjective feeling of wearing off experienced by our patients with dopa-responsive dystonia may have been for one of the nonmotor effects of levodopa, such as mood elevation. Our data provide objective evidence for the often-repeated assertion that motor fluctuations (analogous to those in levodopa-treated patients with Parkinson disease) do not occur in patients with dopa-responsive dystonia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779659     DOI: 10.1001/archneur.55.10.1320

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  1 in total

1.  Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

Authors:  Joanne Terbeek; Sylvia Hermans; Koen Van Laere; Wim Vandenberghe
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.